Hims Stock: The Turnaround Is Only Beginning!
1 extracted signal · 1 resolved · 0 still active
The Patient Investor18 Jun 2026, 19:04 UTC
AI-generated source summary
Barclays has raised its price target for Hims & Hers Health (HIMS) from $29 to $39, maintaining an overweight rating. This adjustment is supported by the company's significant revenue growth and improving Adjusted EBITDA margins, which are projected to reach 11% by FY 2026. The company's strategic investments and M&A activities, particularly in international markets like Canada and Australia, are expected to drive further growth. HIMS's strategy of acquiring and integrating telehealth companies and expanding into new service areas such as weight loss, sexual health, dermatology, and mental health, positions it to capture a substantial share of the growing telehealth market. The company's financial outlook indicates a strong growth trajectory, with projected revenues of $6.5 billion+ and Adjusted EBITDA of $1.3 billion+ by 2030. The valuation metrics, such as the EV/Sales ratio, are considered attractive at around 2.4x, suggesting significant upside potential.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Signals in this source
More Prediction Case Files from The Patient Investor
Why I Don't Own Google Stock & When I'm Buying
The CHEAPEST Quality Stock In The Stock Market!
Intuitive Surgical Stock Analysis! Risks & Upside Potential
There Is NO AI BUBBLE! I’m Buying Every Dip
2 Stocks I'm Buying In The Next 2 Weeks
Netflix Stock Is FINALLY A Buy!
The Patient Investor
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.